In preclinical heart failure models, bile acid receptor agonists improve cardiac metabolism, suppress inflammation, and attenuate ventricular hypertrophy, highlighting their therapeutic potential (Liu et al., 2013). The gene discussed is NR1H4; the disease is heart failure.